Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)

GERMANTOWN, Md., April 5, 2023 /PRNewswire/ -- Deka Biosciences ("Deka"), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject…

Continue ReadingDeka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)